New award for topiramate tablets with xlcare. Ordering period is OCT 31, 2025 to OCT 30, 2026 with four one-year options.

Active Indefinite Delivery Contract Awarded Last action

Contract number
36E79725D0045
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 50% complete
IDV ceiling
$14,134,788.05
Award type
Single award
Set-aside
No set-aside
Competition
Full and Open Competition · 7 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

The Department of Veterans Affairs National Acquisition Center awarded a single-award indefinite-delivery contract to Xlcare Pharmaceuticals Inc. on October 31, 2025, with a ceiling of $14,134,788.05 to supply Topiramate tablets to multiple federal agencies.

Xlcare Pharmaceuticals Inc. is an economically disadvantaged woman-owned small business. The contract covers seven Topiramate tablet configurations ranging from 25mg to 200mg in multiple bottle quantities (60, 500, and 1000 tablets per bottle), with estimated annual requirements ranging from 3,907 to 78,190 tablets by item type. Place of performance encompasses the VA and Department of Defense, with distribution through the VA and DOD Pharmaceutical Prime Vendor Programs to support the VA's Consolidated Mail Outpatient Pharmacy program and subordinate facilities.

The ordering period runs from October 31, 2025, through October 30, 2026, with four additional one-year options exercisable through October 30, 2027. The source reflects a modification to exercise Option Year 1 for the underlying contract. The procurement was issued unrestricted, without set-aside designation, under NAICS code 325412 (Pharmaceutical Preparation Manufacturing). The solicitation, posted March 26, 2025, closed April 29, 2025, and required offerors to specify exact drug names and unique NDC numbers. The contract will serve the VA, Department of Defense, Bureau of Prisons, and Indian Health Service.

Transactions

Action Obligated Date
Exercise an Option P00002 · Modification to exercise option year 1 for national contract 36E79725D0045. $0
Supplemental Agreement for work within scope P00001 · Modification to incorporate EO 14398 DEI discrimination into national contract 36E79725D0045. $0
Original award $0

Quick answers

Who was awarded contract 36E79725D0045?

36E79725D0045 was awarded to Xlcare Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on October 31, 2025.

How much is contract 36E79725D0045 worth?

36E79725D0045's own ceiling is $14,134,788.

Who can order from contract 36E79725D0045?

36E79725D0045 is a single award indefinite delivery contract.

Was contract 36E79725D0045 competed?

The extent of competition for 36E79725D0045 was full and open competition. The government received 7 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV